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Open access unda b s t r a c t
Apigenin has been reported to inhibit proliferation of cancer cells; however, the mechanism underlying its
action is not completely understood. Here, we evaluated the effects of apigenin on the levels of expression
and activity of antioxidant enzymes, and the involvement of ROS in the mechanism of cell death induced
by apigenin in HepG2 human hepatoma cells. Upon treatment with apigenin, HepG2 cells displayed a
reduction in cell viability in a dose- and time-dependent manner, and some morphological changes. In
addition, apigenin treatment induced ROS generation and signiﬁcantly decreased the mRNA levels and
activity of catalase and levels of intracellular GSH. On the other hand, apigenin treatment did not alter
the expression or activity levels of other antioxidant enzymes. Addition of exogenous catalase signiﬁcantly
reduced the effects of apigenin on HepG2 cell death. We also demonstrated that HepG2 cells aremore sen-
sitive to apigenin-mediated cell death than are primary cultures of mouse hepatocytes, suggesting a dif-
ferential toxic effect of this agent in tumor cells. Our results suggest that apigenin-induced apoptosis in
HepG2 cells may be mediated by a H2O2-dependent pathway via reduction of the antioxidant defenses.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1 The abbreviations used are: ROS, reactive oxygen species; H2O2, hydrogen
peroxide; NADPH, nicotinamide adenine dinucleotide phosphate; BHA, butylated1. Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most prevalent can-
cer worldwide, especially in regions where hepatitis B is endemic,
such as China, southeast Asia, and southern Africa. The incidence of
HCC has tripled in the United States over the past two decades as a
result of an increase in hepatitis C infections [1,2]. Current treat-
ment options for HCC remain limited, therefore, development of
more-effective therapeutic tools and strategies is greatly desirable
[3]. In order to develop an effective drug against several types of
cancer, considerable attention has been devoted to identifying
plant-derived compounds displaying anti-tumor activity, such as
the ﬂavonoids [4].
Apigenin (5,7,40-trihydroxyﬂavone), a naturally occurring plant
ﬂavonoid, is abundant in vegetables and fruits [5]. Apigenin is a
bioactive ﬂavonoid with anti-inﬂammatory, antioxidant, and anti-
cancer properties against several human-cancer cell lines [6],
including prostate carcinoma [7,8], colon carcinoma [9], breast
cancer [10], leukemia cells [11], cervical carcinoma [12], lung
cancer [13], and hepatoma [14,15].x: +55 41 3266 2042.
in.rocha@gmail.com (M.E.M.
er the Elsevier OA license.The cellular effects of apigenin are associated with cell-cycle ar-
rest and apoptosis in a wide range of malignant cells [11,16,17].
Exposure of a wide array of malignant cells to apigenin induces a
reversible G2/M and G0/G1 arrest by inhibiting p34cdc2 kinase
activity [9], and increasing p53 protein stability [18,19]. Apigenin
is able to increase p21 levels, resulting in arrest of the cell cycle
and apoptosis in several cancer cell lines, regardless of the Rb sta-
tus and p53 involvement [20,21,12,14]. Apigenin also induces
apoptosis by alteration of the Bax/Bcl-2 ratio, release of cyto-
chrome c, and induction of Apaf-1, leading to caspase activation
and PARP-cleavage [21,13,11,12,22].
Accumulated evidence indicates that apigenin can suppress the
growth of hepatocarcinoma cells by arresting the cell cycle, which
is associated with an accumulation of p53 tumor-suppressor pro-
tein and induction of p21 expression [14] and caspase-mediated
apoptosis [23], also causing a dose-dependent elevation of intracel-
lular ROS1 levels.hydroxy anisole; BHT, butylated hydroxy toluene; EtOH, ethanol; Tris, tris(hydroxy-
methyl)aminomethane; NaCl, sodium chloride; PCR, polymerase chain reaction; DCF-
DA, 20 ,70-dichloroﬂuorescin diacetate; SOD, superoxide dismutase; CAT, catalase; GPx,
glutathione peroxidase; Gred, glutathione reductase; BSO, buthionine sulfoximine.
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resulted in mitochondrial membrane depolarization, intracellular
ROS generation, activation of caspases (-3, -9 and -8) and induction
of apoptosis [22]. Apigenin also induces apoptosis in prostate epi-
thelial cells through ROS generation, which interferes with mito-
chondrial functions and leads to mitochondrial permeability
transition [8]. In addition, treatment with various inhibitors of
NADPH oxidase signiﬁcantly abrogated both the generation of
ROS and the induction of apoptosis by apigenin. These results sug-
gest that ROS generated through the activation of NADPH oxidase
may play an essential role in the apigenin-induced apoptosis in
HepG2 cells [15].
Intracellular generation of H2O2, the most stable ROS, has been
considered an important mediator of apoptosis. H2O2 can also alter
protein activity through oxidative modiﬁcation of regulatory pro-
tein complexes (e.g., the Nrf2/Keap1 system). The Nrf2 transcrip-
tion factor regulates the expression of antioxidant enzymes and
xenobiotic detoxiﬁcation. Nrf2 promotes activation of genes
containing antioxidant response elements (AREs), such as the
phase-2 genes encoding heme oxygenase, quinine oxidoreductase,
c-glutamylcysteine synthase, glutathione S-transferase (GST), cat-
alase, superoxide dismutase (MnSOD) and other antioxidant-func-
tion genes, their expression being induced upon cells’ exposure to
oxidative stress [24]. Flavonoids have recently been demonstrated
to favor both Nrf2 nuclear translocation and eventually ARE activa-
tion in several cell lines.
GSH is involved in several important cellular functions, such as
chemical detoxiﬁcation and antioxidant defense. The GSH to GSSG
cellular ratio, which under physiological conditions is around 100
to 1 in the liver, decreases during oxidative stress and apoptosis.
Altered GSH redox state triggers the unfolding protein response
and apoptosis [25].
Although prior studies have shown that apigenin-induced
ROS-dependent apoptosis occurs in liver cancer and other malig-
nancies, the pathways whereby apigenin leads to ROS generation
and execution of the apoptosis program are still not well
characterized.
The main purpose of the present study was to investigate
whether the mRNA levels and activity of different antioxidant en-
zymes (such as SOD, catalase, GPx, GRed), GSH levels and ROS gen-
eration are affected by apigenin and whether these alterations
could be associated with the mechanism of apoptosis induced by
apigenin in HepG2 human hepatoma cells.
Our results indicate that catalase downregulation (mRNA
expression levels and protein activity) may play an essential role
in apigenin-induced apoptosis in HepG2 cells, since catalase added
to the culture medium partially protected from apigenin-induced
cell death, suggesting the direct involvement of H2O2 in the apop-
totic mechanism induced by apigenin in HepG2 human hepatoma
cells. Together, our results suggest that the effects of apigenin
could contribute to ROS generation, GSH depletion and apoptotic
cell death in HepG2 human hepatoma cells, opening new avenues
for therapeutic strategies.2. Materials and methods
2.1. Materials
DMEM high-glucose medium and fetal bovine serum (FBS)
were obtained from Cultilab (Campinas, Brazil). Apigenin, crystal
violet, NADPH, cytochrome c and DCF–DA were obtained from
Sigma–Aldrich (St. Louis, MO, USA). Dimethyl sulfoxide (DMSO)
was obtained from Merck (São Paulo, SP, Brazil). All other re-
agents were commercial products of the highest available purity
grade.2.2. Apigenin solutions
Apigenin (100 mmol/L) was dissolved in DMSO and then further
diluted in DMEM high-glucose medium (10–100 lmol/L). The api-
genin stock solution was stored at 20 C and warmed to 25 C be-
fore use.
2.3. HepG2 cell culture
The human hepatocarcinoma HepG2 cell line (from the Ameri-
can Type Culture Collection – ATCC) was maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM high-glucose), supplemented
with 10% fetal bovine serum (FBS) and 50 lg/mL gentamycin, at
37 C, 5% CO2 under controlled humidity.
2.4. Primary culture of mouse hepatocytes
Male mice from the Central Animal House of the Federal
University of Paraná, which received a standard laboratory diet
(Purina), were euthanized (with 4 mg/kg xylazine/0.6 mg/kg ace-
promazine/60 mg/kg ketamine) and manipulated, using aseptic
techniques, under a laminar airﬂow. All recommendations of the
Brazilian national regulations for scientiﬁc management of animals
(No. 6638, 05/11/1979) were respected. The liver was transferred
to Ca2+ and Mg2+-free phosphate buffered saline (PBS), washed
three times with PBS, minced with scissors and then centrifuged
at 2000g for 3 min. The material was incubated with 1 mg/mL col-
lagenase (Sigma) for 3 min in a 37 C incubator. After tissue diges-
tion, the supernatant was centrifuged at 2000g for 3 min. The pellet
was resuspended in high-glucose DMEM supplemented with 10%
FBS and seeded onto P60 mm plates. This operation was repeated
three more times, increasing the incubation period in the presence
of collagenase. The culture was maintained in a humidiﬁed atmo-
sphere in 5% CO2 at 37 C.
2.5. Cell viability assays
HepG2 cells were seeded at a density of 2.5  104 cells/well into
24-well culture plates. After overnight incubation, the cells were
treated with varying concentrations of apigenin (0, 10, 25, 50, or
100 lmol/L) for 24, 48, 96, or 144 h. For catalase protection assays,
the cells were seeded at a density of 1  104 cells/well into 96-well
culture plates. After overnight incubation, the cells were simulta-
neously treated with 100 lmol/L apigenin and exogenous catalase
(100, 250, 500, or 1000 U/mL), BHA or BHT (10, 50, or 100 lmol/L),
or ascorbic acid (100, 250, or 500 lmol/L) for 24 h. To assess the
viability of the hepatocyte cells, the cells were seeded at a density
of 1  104 cells/well into 96-well culture plates. After overnight
incubation, the cells were treated with 10, 25, 50, or 100 lmol/L
apigenin for 24 or 48 h. Cell viability was evaluated through the
crystal violet staining assay, as described by Kueng et al. (1989)
[26], and absorbance was determined at 550 nm, using an Inﬁnite
200 TECAN microplate reader. Control experiments were per-
formed with high-glucose DMEM containing 0.1% DMSO (v/v).
The results were expressed as a percentage of viable cells in com-
parison to the control (100%).
2.6. Determination of cytochrome c release
Cells were seeded at a density of 1  106 cells onto a 60-mm
plate. After overnight incubation, the cultures were treated with
apigenin (100 lmol/L) for 24 h and then washed with phosphate-
buffered saline (PBS) pH 7.2. Cells were harvested and permeabili-
zed with 10 lmol/L digitonin for 30 min at 4 C in a solution con-
taining 10 mg/ml Tris–HCl (pH 7.0), 3 mg/mL ethylene glycol
tetra-acetic acid (EGTA), and 50 lg/mL sucrose. The cells were then
Table 1
Nucleotide sequences of PCR primers used for quantitative real-time RT-PCR.
Gene Oligonucleotide primers
hCuZnSOO F: 50-GTGCAGGGCATCATCAATTTC-30
R: 50-AATCCATGCAQGCCTTCAGT-30
hZnSOD F: 50-GGACACTTACAAATTGCTGCTTGT-30
R: 50-AGTAAGCGTGCTCCCACACAT-30
hCAT F: 50-GATAGCCTTCGACCCAAGCA-30
R: 50-ATGGCGGTGAGTGTCAGGAT-30
hGSR F: 50-GTGGCACTTGCGTGAATGTT-30
R: 50-GGAAAGCCATAATCAGCATGATC-30
hGpxl F: 50-TGCTGGCCTCCCCTTACAG-30
R: 50-GCACACATGGCGCAATTG-30
hGAPDH F: 50-ACCCACTCCTCCACCTTTGA-30
R: 50-CTGTTGCTGTAGCCAAATTCGT-30
hTubuin F: 50-TCAACACCTTCTTCAGTGAAACG-30
R: 50-AGTGGCAGTGCGAACTTCATC-30
hHPRT F: 50-GAACGTCTTGCTCGAGATGTGA-30
R: 50-TCCAGCAGGTCAGCAAAGAAT-30
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through a 0.2 lm ﬁlter. Cytochrome c release was evaluated by
the method of Appaix et al. (2000) [27]. The absorbance of clariﬁed
supernatants was recorded at 414 nm, using the medium as a
blank, in a spectrophotometer (Shimadzu UV-2450). The values
were calculated based on e = 100 mmol1 cm1 of cytochrome c
at 414 nm [27].
2.7. Cell-cycle analysis
Cells were seeded at a density of 1  106 cells onto a 60-mm
plate. After overnight incubation, the cultures were treated with
apigenin (100 lmol/L) for 24 h, and then the culture supernatants
and the adhered cells were collected. The samples were centri-
fuged at 2000g for 5 min, and the cell pellet was resuspended in
0.5 mL of PBS and 4.5 mL of cold 70% EtOH, and stored at 4 C.
For ﬂow-cytometry analysis, the cell pellet was again collected
by centrifugation, and 0.3 mL of propidium iodide (PI) staining
solution (50 lg/mL) was added to the samples. The samples were
analyzed in a FC500 ﬂow cytometer (Beckman Counter) and the re-
sults were calculated using the MXP software.
2.8. Optical microscopy analysis
HepG2 cells (2.5  104 cells/well) were seeded onto 24-well
cell-culture plates containing glass coverslips. After overnight
incubation, the cultures were treated with apigenin (100 lmol/L)
for 24 or 48 h. After treatment, the coverslips were removed and
the cells were immediately ﬁxed in absolute ethanol and then
stained with hematoxylin–eosin. The cells were evaluated by
means of BEL Photonics microscopy.
2.9. Determination of GSSG and GSH levels
HepG2 cells were treated with apigenin (25, 50 and 100 lmol/L)
or with buthionine sulfoximine (BSO) (50 lmol/L) for 24 h. To
measure the levels of GSH and GSSG, we followed the protocols
of Grifﬁth (1980) [28] and Rahman et al. (2007) [29] with the fol-
lowing modiﬁcations: after treatment, the supernatant was re-
moved and cells were washed with PBS. HCl was added
(10 mmol/L) and cells were lysed by freezing and thawing process.
After an equal volume of 5-sulfosalicylic acid was added, the sam-
ples were maintained on ice for 5 min and then centrifuged
(10,000g/10 min, 4 C). The supernatant was collected and sepa-
rated it into two equal aliquots of 100 lL (for GSx and for GSSG).
To measure GSSG, 2-vinylpyridine was added (2%, v/v), the solution
was mixed and kept for 1 h in ice. Upon neutralization by the addi-
tion of triethanolamine (0.5 mmol/L), 50 lL of each sample were
distributed for quantiﬁcation of total GS per well of a 96-well plate
and 60 lL for GSSG.
2.10. Measurement of intracellular ROS generation
Intracellular ROS generation was determined as described by
Wan et al. (2003) [30]. Cells were seeded at a density of
1  104 cells/well in 96-well plates. After overnight incubation,
the cultures were washed twice with PBS and incubated for
30 min with 50 lmol/L of 20,70-dichloroﬂuorescein diacetate
(DCFH–DA) diluted in PBS. At the end of the incubation period,
the cultures were again washed twice with PBS and treated with
100 lmol/L apigenin and 400 lmol/L H2O2 as a positive control.
Immediately after the treatment period, the plates were read using
an Inﬁnite 200 TECAN microplate reader at excitation and emis-
sion wavelengths of 485 and 525 nm, respectively. The level of cel-
lular ﬂuorescence, measured in relative ﬂuorescence units (RFU),was converted as a percentage compared to control cells, which
were arbitrarily assigned the value of 100%.
2.11. RNA isolation and ﬁrst-strand cDNA synthesis
Cells were seeded at a density of 1  106 cells/well onto a
60 mm plate. After overnight incubation, the cultures were treated
with apigenin (100 lmol/L) for 24 h. Total RNA was isolated using
the spin Mini RNA isolation kit (Qiagen), according to the manufac-
turer’s instructions, and stored at 80 C. One microgram of total
RNA was reverse-transcribed using oligo(dT) and Superscript III
Reverse Transcriptase (Invitrogen). cDNA synthesis was carried
out according to the manufacturer’s instructions, and the resulting
cDNA was stored at 20 C.
2.12. Quantiﬁcation of mRNA levels by real-time RT-PCR
Using cDNAs as the template, quantitative real-time PCR was
carried out using the SYBR Green PCR Master Mix (Applied Biosys-
tems) in a StepOnePlus™ Real-Time PCR Detection System (Ap-
plied Biosystems), according to the manufacturer’s instructions,
using speciﬁc oligonucleotide primers for human CuZnSOD,
MnSOD, CAT, Gred, and Gpx1 genes. A dissociation cycle was per-
formed after each run to check for non-speciﬁc ampliﬁcation or
contamination. The mRNA expression levels were normalized
using the geNorm 3.4 software [31], and the corresponding HPRT,
Tubulin, and GAPDH housekeeping gene expression levels. Relative
expression levels were estimated using the method described by
Pfafﬂ (2001) [32]. Sets of speciﬁc primers were designed, using
the Primer Express (Applied Biosystems) software and validated
through BLAST and BLAT, and their sequences are shown in Table 1.
2.13. Enzymatic activity assays
After incubation with apigenin (100 lmol/L) for 24 h, HepG2
cultures were washed with PBS and the cells were collected, resus-
pended in PBS, and sonicated on ice (three times for 20 s). This sus-
pension was centrifuged for 10 min at 13,000g (4 C) in a
microcentrifuge, and the supernatant was used for enzymatic
activity assays. Antioxidant enzyme activities were determined
with a spectrophotometer (Shimadzu UV-2450). Catalase (E.C.
1.11.1.6) was determined by following the decrease in absorbance
at 240 nm, using hydrogen peroxide as the substrate [33]. Superox-
ide dismutase (SOD) (E.C. 1.15.1.1) was measured by monitoring
the inhibition of epinephrine auto-oxidation at 480 nm [34]. Cata-
lase activity was previously calculated as nmol of H2O2 consumed
min1 mg1 protein, and SOD activity as U/mg protein. For total
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responds to 50% inhibition of activity). Glutathione reductase (E.C.
1.6.4.2) activity was measured using the method of Sies et al.
(1979) [35]. Glutathione reductase activity was calculated as pmol
of NADPH consumed/min/mg protein. Enzyme activities were ex-
pressed as percentages of the control (100%).
2.14. Protein determination
Total protein concentration was performed by the Bradford
method (1976). [36], calibrated with bovine serum albumin.
2.15. Statistical analysis
Statistical analysis was carried out by analysis of variance (one-
way ANOVA) followed by a Tukey test or Kruskal–Wallis/Dunn’s
Multiple comparison test for comparison of the means, using the
Graph Pad Prism 5 program. Values for means ± SD were used.
For all comparisons, differences were considered statistically sig-
niﬁcant at p < 0.05.3. Results
3.1. Apigenin induces inhibition of cell growth, cytochrome c release,
and DNA fragmentation in HepG2 cells
In order to assess the effects of apigenin in the human hep-
atoma model, HepG2 cells were exposed to different concentra-Fig. 1. Effects of apigenin on cell viability, cytochrome c release, and DNA fragmentation
mean ± SD of percentage of viable cells in comparison to the control (data represent three
found in the percentage of cell death at all doses tested. (B) Release of cytochrome c fro
percentage relative to control (100%) of ﬁve independent experiments, each in tripl
min1 mg1 protein. ⁄⁄⁄p < 0.001. (C) Flow cytometry analysis of PI-stained HepG2 cel
intensity and the y-axis represents cell number. The sub-G1 peak, designated as A, was
designated B, C, and D, respectively. Data represent three independent experiments, eactions of apigenin (10–100 lmol/L) for 24, 48, 96, or 144 h, and
then cellular viability was determined by violet crystal staining.
Addition of apigenin decreased cell viability in a dose- and
time-dependent manner, as depicted in Fig. 1A. Treatment for
24 h with the lowest dose (10 lmol/L) signiﬁcantly decreased
cell viability (16.7%), and produced an approximately 40%
reduction in cell viability when these cells were treated with
the highest dose (100 lmol/L). Apigenin (100 lmol/L) treatment
of HepG2 cells for 6 days caused more than 80% reduction in
cell viability.
In order to better understand the mechanism of cell death in-
duced by apigenin, HepG2 cells were treated with apigenin
(100 lmol/L) for 24 h and then analyzed for DNA fragmentation
and cytochrome c release. A signiﬁcant increase (>2-fold) in cyto-
chrome c release to the cytoplasm was observed after apigenin
treatment (Fig. 1B). In addition, apigenin also induced DNA frag-
mentation, as assessed by determining the hypodiploid DNA con-
tent after staining with propidium iodide, with a concomitant
decrease in the percentage of cells in the G1 phase, compared to
untreated control cultures (Fig. 1C).3.2. Morphological analysis
The HepG2 cells exposed to 100 lmol/L of apigenin for 24 and
48 h showed discreet morphological changes, evidenced by the lost
of cellular limits and alterations in cell volume (Fig. 2C and Fig. 2D).
Control cultures treated with vehicle (0.1% DMSO) did not have an
apparent effect compared to untreated controls.. (A) Viability of the HepG2 cell line after apigenin treatment. Values represent the
independent experiments, each in triplicate). Signiﬁcant differences (p < 0.05) were
m mitochondria, caused by apigenin treatment (100 lmol/L). Data are shown as a
icate. Control (100%) corresponds to 1.12 ± 0.24 nmol of cytochrome c released.
ls treated with apigenin (100 lmol/L). The x-axis represents relative ﬂuorescence
deﬁned by cells undergoing DNA fragmentation. The G1, S/G2, and M phases were
h in triplicate.
Fig. 2. Morphological assessment of HepG2 cells after treatment with apigenin (100 lmol/L) for 24 and 48 h. Optical microscopy analysis (230). (a) Control 24 h; (b) Control
48 h; (c) Apigenin (100 lmol/L) treatment for 24 h. (d) Apigenin (100 lmol./L) treatment for 48 h.
Fig. 3. ROS generation after apigenin treatment of HepG2 cells. HepG2 cells were preloaded with DCFH–DA substrate in PBS and treated with apigenin (100 lmol/L). The
ﬂuorescence was read at the indicated time periods. The experiments represent the mean ± SD of ﬂuorescence percentage with respect to the control, of three independent
experiments, each in triplicate.
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of antioxidant enzymes
HepG2 cells were treated with apigenin (100 lmol/L), and ROS
generation was measured using ﬂuorometric analysis. Treatment
with H2O2 (400 lmol/L) was used as a positive control. The apige-
nin treatment led to enhanced generation of ROS, as a function of
time, up to 60 min of treatment, after which the effect reached a
plateau (Fig. 3).
The expression levels of CAT, CuZnSOD, MnSOD, GPx1, and Gred
by qRT-PCR in HepG2 cells were examined upon treatment with
apigenin (100 lmol/L) for 24 h. Apigenin-treated HepG2 cells dis-
played signiﬁcantly lower CAT mRNA levels (p < 0.001) (Fig. 4A).
The mRNA expression levels of MnSOD, CuZnSOD, GPx1, and Gred
were not altered under these conditions (Fig. 4A). The relative
mRNA expression data were normalized using the geNorm 3.4
software [31], and the corresponding housekeeping genes HPRT,
Tubulin, and GAPDH.
In addition, the effects of apigenin on the activity of antioxidant
enzymes were evaluated. The results (Fig. 4B) showed that onlycatalase activity was signiﬁcantly inhibited, by approximately
20% (p < 0.001), in HepG2 cells treated with apigenin (100 lmol/L
for 24 h).
3.4. Catalase protection of HepG2 cell death
In order to determine whether downregulation of catalase plays
an essential role in the mechanism of apigenin-induced apoptosis,
cells were treated simultaneously with apigenin (100 lmol/L) and
different concentrations of exogenous catalase for 24 h. Cell viabil-
ity was evaluated using the crystal violet staining assay. The results
(Fig. 5A) demonstrated that addition of exogenous catalase (500 U/
mL and 1000 U/mL) resulted in a signiﬁcant reduction of the effect
of apigenin on HepG2 cell death, by approximately 20% (p < 0.01)
and 30% (p < 0.001), respectively.
Interestingly, when HepG2 cells were co-treated with apigenin
(100 lmol/L) in the presence or in the absence of other antioxidant
compounds without speciﬁcities for H2O2 decomposition, such as
BHA, BHT, and ascorbic acid, no signiﬁcant reduction in the per-
centage of cell death was observed (Fig. 5B).
Fig. 4. Effects of apigenin on mRNA expression levels and activity of antioxidant enzymes in HepG2 cells. (A) Quantiﬁcation of transcript levels of antioxidant enzymes. The
data represent the mean ± SD of three independent experiments, each in triplicate. (B) Effects of apigenin (100 lmol/L) on activity of antioxidant enzymes. Data are presented
as a percentage relative to control (100%) of three independent experiments, each performed in triplicate. For catalase data, control (100%) corresponds to 0.853 nmol of H2O2
consumed (lg protein min1). For total SOD, control (100%) corresponds to 1 unit of SOD (1 SOD unit corresponds to 50% inhibition of activity). For the Gred data, control
(100%) corresponds to 0.14 nmol of NADPH consumed (lg protein.min1). ⁄p < 0.001 and ⁄⁄⁄p < 0.001.
Fig. 5. Effects of co-treatment with apigenin and antioxidant compounds on viability of HepG2 cells. (A) Cells were co-treated with apigenin (100 lmol/L) and different
exogenous catalase concentrations for 24 h. (B) Co-treatment with apigenin (100 lmol/L) and BHA or BHT or ascorbic acid at different concentrations for 24 h. Values
represent the mean ± SD of percentage of viable cells in comparison to untreated control (data represent three independent experiments, each in triplicate). ⁄p < 0.05,
⁄⁄p < 0.01, and ⁄⁄⁄p < 0.001 versus control.
Fig. 6. GSH levels and GSH/GSSG ratio in apigenin-treated HepG2 cells. Cells were treated with 0 (untreated), 25, 50 and 100 lM apigenin for 24 h. Glutathione depletion with
GSH neosynthesis inhibitor buthionine sulfoximine (BSO) was used as a control. (A) GSH depletion analysis in apigenin-treated HepG2 cells. Data are shown as a percentage
relative to control (100%) of three independent experiments, each in triplicate. Values are expressed as mean ± SD. (B) Apigenin reduces the GSH/GSSG ratio in HepG2 cells.
Data represent three independent experiments, each in triplicate. Values are expressed as mean ± SD. ⁄p < 0.05, ⁄⁄p < 0.01.
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Fig. 7. Cell viability of mouse hepatocytes after apigenin treatment. Cell viability
assessed by crystal violet staining after 24 and 48 h of treatment with apigenin, as
indicated. Values represent the mean ± SD of percentage of cell viability with
respect to the untreated control. Data represent two independent experiments,
each in triplicate.
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HepG2 cells treated with apigenin (50 and 100 lmol/L) for 24 h
displayed reduced GSH levels (Fig. 6A). Pharmacological glutathi-
one depletion with GSH neosynthesis inhibitor buthionine sulfox-
imine (BSO) was used as a control. The GSH levels were reduced by
48% and 46% relative to the control condition in the presence of 50
and 100 lmol/L of apigenin, respectively (p < 0.05). We also ob-
served a signiﬁcant decrease (approximately 50%) in the GSH/GSSG
ratio in HepG2 cells after apigenin treatment (50 and 100 lmol/L,
for 24 h) (p < 0.05) (Fig. 6B).
3.6. Differential sensitivity of human hepatoma cells versus primary
mouse hepatocytes to the growth-inhibitory effects of apigenin
Agents that are capable of inducing selective apoptosis of cancer
cells are receiving considerable attention, in the effort to develop
novel approaches to prevent cancer. In order to evaluate the
growth-inhibitory effects of apigenin in normal versus tumor cells,
primary monolayer cultures of adult mouse hepatocytes were trea-
ted with different concentrations of apigenin for 24 and 48 h. Our
results showed (Fig. 7) that the growth of primary mouse hepato-
cytes was not inhibited by the apigenin treatment at lower levels,
when compared with the effects observed for the HepG2 cell line
(Fig. 1A).4. Discussion
Cell apoptosis is initiated by extracellular and intracellular sig-
nals via two main pathways, namely, the death receptor- and the
mitochondrial-mediated pathways; in both of which ROS play an
important role. The extrinsic apoptosis pathway is mediated by
death receptors in which ligand-receptor binding initiates pro-
tein–protein interactions at the cell membrane, activating initiator
caspases. Recent evidence suggests a possible direct role for ROS in
mediating death receptor activation and apoptotic induction
through ROS-induced receptor clustering and the formation of li-
pid-raft-derived signaling platforms [25]. The stimulation of the
intrinsic mitochondrial apoptotic pathway by ROS and mitochon-
drial DNA damage promotes outer membrane permeabilization
and mitochondria-to-cytosol translocation of cytochrome c, AIF
or Smac/Diablo, which triggers caspase-dependent or caspase-
independent cytosolic signaling events [37,38]. Mitochondrial
permeabilization, permeability transition pore processes, and the
release of apoptogenic factors are observed. However, JNK
activation by ROS may induce both extrinsic or intrinsic apoptoticsignaling [39]. ROS-mediated apoptotic signaling is associated with
decreased cellular GSH levels and loss of the cellular redox balance
[40]. Decreased cell GSH can be generated by ROS-induced GSH
oxidation or GSH export from cells. It was demonstrated that
GSH loss due to decreased de novo GSH synthesis triggered redox
activation of protein kinase C and through GSH efﬂux, induced
JNK-dependent apoptosis [41,42]. GSH oxidation is a major con-
tributor to cell apoptosis mediated by oxidants through activation
of mitochondrial apoptotic signaling. It has been observed that
post-oxidant recovery of the cellular GSH/GSSG redox status did
not inﬂuence the apoptotic outcome, indicating that oxidant-
induced apoptotic initiation occurred within an early and narrow
window of the GSH/GSSG redox shift [43].
Previous reports have demonstrated a dose-dependent inhibi-
tion of cell viability and induction of apoptosis by apigenin in sev-
eral human cancer cell lines, such as the cervical carcinoma HeLa
cells [12], leukemia HL-60 cells [11], breast cancer cell lines [10],
prostate epithelial cells [8], prostatic adenocarcinoma LNCaP cells
[20], lung cancer A549 cells [13], and HepG2 hepatoma cells
[14,23,15]. In addition, the role of ROS as a mediator of the apopto-
sis induced by apigenin has been established [22]. However, the
signaling pathways whereby apigenin leads to ROS generation
and execution of the apoptosis program are still not fully
characterized.
To further elucidate the mechanisms of apigenin-induced cell
death in HepG2 cells, we initially evaluated morphological altera-
tions induced by this ﬂavone and biochemical markers of apopto-
sis. The results indicated that apigenin induced morphological
changes (Fig. 2), suggesting cell suffering, however, to clarify the
morphological changes induced by apigenin, further experiments
such as electron microscopy are required. In addition, our results
showed that apigenin treatment leads to a decreased percentage
of viable cells (Fig. 1A), cytochrome c release from mitochondria
(Fig. 1B), and DNA fragmentation (Fig. 1C), consistent with the
apoptotic process. DCF assays also conﬁrmed apigenin-induced
ROS generation (Fig. 3). These data are in agreement with those
of Choi et al. (2007) [15], who observed increased levels of intracel-
lular ROS in apigenin-treated HepG2 cells. The cytochrome c re-
lease and DNA fragmentation promoted by apigenin in HepG2
cells, observed in this study, are in agreement with data reported
by different authors upon treatment of other cell lines with apige-
nin [11,8,13]. Together, our results provide evidence that apigenin
treatment promotes the apoptotic pathway in HepG2 cells in a
dose- and time-dependent manner.
It is recognized that intracellular generation of H2O2 is an
important mediator of apoptosis. Different enzymes such as perox-
idases, catalase, and superoxide dismutase are involved in H2O2
modulation. Interestingly, it has been reported that overexpression
of human catalase in HepG2 cells promotes a protective effect
against cytotoxicity or apoptosis induced by oxidative stress [44].
The effects of apigenin on the expression and activity of antiox-
idant enzymes that modulate H2O2 levels, such as catalase (CAT),
superoxide dismutase (CuZnSOD and MnSOD), glutathione peroxi-
dase (GPx), and glutathione reductase (Gred), in HepG2 cells had
not been previously described. Here, we analyzed the effects of api-
genin on these enzymes. In addition, we correlated the effects of
apigenin on H2O2 modulation with HepG2 cell proliferation.
Our results demonstrated that apigenin treatment promotes
downregulation of catalase mRNA expression levels and reduction
of its activity (Fig. 4A and B), suggesting that increased H2O2 levels
could be involved in the HepG2 cell death induced by apigenin.
In order to validate our hypothesis, we evaluated the effect of
concomitant treatment of HepG2 cells with both apigenin and
exogenous catalase. In the presence of exogenous catalase, we ob-
served protection from apigenin-induced cell death in a dose-
dependent manner (Fig. 5A). These results showed that catalase
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essential role in apigenin-induced apoptosis in HepG2 cells, sug-
gesting the direct involvement of H2O2 in the apoptotic mechanism
induced by apigenin in these cells. Supporting this hypothesis, con-
comitant treatment with apigenin and other antioxidant com-
pounds (which are able to promote scavenging of free radicals,
but do not act directly on H2O2) had no effect on HepG2 cell death
(Fig. 5B).
Several recent reports have suggested a role for ROS in apopto-
sis induced by drugs, including certain chemopreventive agents,
through the engagement of downstream proteins involved in the
execution of apoptosis [45–48]. Previous reports demonstrated
that apigenin-induced apoptosis in different cell lines (including
HepG2 cells) occurs through an increase in p53 and p21 protein
levels, suggesting a p53-dependent apoptosis pathway [14,12]. In
agreement with our results, a recent study using the prostate can-
cer 22Rv1 cell line found that addition of H2O2 or apigenin in-
creased ROS generation, with concomitant increases in p53 and
p21 protein expression, which correlated with increased apoptosis.
These effects were alleviated by pretreatment of cells with exoge-
nous catalase [22]. In addition, these authors observed that apige-
nin promotes decreased levels of Bcl-XL and Bcl-2 and increased
Bax, triggering caspase activation; and, also, that treatment with
the Z-VAD-FMK and DEVD-CHO caspase inhibitors partially res-
cued these cells from apigenin-induced apoptosis [22]. These data
support our hypothesis that increased intracellular H2O2, induced
by apigenin treatment, may be responsible for triggering the apop-
totic pathway. We suggest that these effects of apigenin in p53 and
other cell-cycle checkpoints, can be attributed at least in part to
accumulation of ROS, due to direct effects of apigenin on some
antioxidant enzymes, especially those involved in the control of
H2O2 levels.
Wang et al. (1999) observed that apoptosis induced by ﬂavo-
noids (including apigenin) is stimulated by the release of cyto-
chrome c to the cytosol, by procaspase-9 processing as well as
through a caspase-3 dependent mechanism in leukemia HL-60
cells [11].
Direct ROS effects on caspase activation have been documented.
Redox-active catalytic site cysteines of caspases are prone to oxida-
tion, nitrosation, or glutathiolation [49]. Thus, H2O2 derived from
endogenous and exogenous sources has been shown to induce
reversible inactivation of caspase 3 and 8 through oxidation of
their catalytic site cysteines [50]. For caspase-9, H2O2-induced en-
zyme inactivation was speciﬁcally mediated through iron-cata-
lyzed oxidation of the catalytic site cysteine in procaspase-9 [51].
Mitochondrial procaspase-9 activation occurred during the prea-
poptotic phase before cytochrome c release, suggesting that this
mechanism could amplify the proapoptotic effect of cytochrome
c [52].
Together, our results show that catalase downregulation
(mRNA expression levels and activity) plays an essential role in
apigenin-induced apoptosis in HepG2 cells, since the addition of
this enzyme to the culture medium partially protected from api-
genin-induced cell death, suggesting the direct involvement of
H2O2 in the apoptotic mechanism induced by apigenin in HepG2
hepatoma cells.
Recently, it has been observed that the mRNA expression levels
of antioxidant enzymes are regulated by the Nrf2–Keap1 complex
[53]. Nrf2, a ubiquitous protein, is a member of the subfamily of
transcription factors [54]. Nrf2 is sequestered in cytoplasm by vir-
tue of its binding to the Kelch-like ECH-associated protein, Keap1,
with Nrf2 being led to ubiquitination and proteosomal degrada-
tion. However, when reactive oxygen species and reactive nitrogen
species are generated, and exogenous Nrf2 inducers such as che-
mopreventive agents are used, the Nrf2–Keap1 complex disassoci-
ates, and Nrf2 translocates to the nucleus, where it activates thetranscription of detoxifying enzyme genes by biding to ARE (anti-
oxidant response element).
Flavonoids have recently been demonstrated to favor both Nrf2
nuclear translocation and eventually AREs activation in several cell
lines [53]. Nrf2 activation results in transcriptional expression of
some protective enzymes, including copper/zinc superoxide dis-
mutase (CuZnSOD), manganese (mitochondrial) superoxide dismu-
tase (MnSOD), glutathione S-transferase (GST) and catalase [24,55].
Here, we show that HepG2 cells treated with apigenin display
reduced intracellular GSH levels and GSH/GSSG ratio (Fig. 6A and
B). Our data are in agreement with recent previously report data
in which apigenin treatment induced intracellular GSH depletion
and ROS accumulation in prostate cancer cells [22]. The catalytic
and the regulatory subunits of c-glutamylcysteine ligase, the en-
zyme that catalyzes the rate-limiting step in the biosynthesis of
glutathione, are regulated by Nrf2 [56]. The cystine/glutamate
membrane transporter, which is important for glutathione synthe-
sis, is an Nrf2 target [57,58]. Glutathione is used by glutathione
peroxidases to reduce hydrogen peroxide to water, and glutathione
reductase is Nrf2-dependent [59]. Intracellular loss of GSH is an
early hallmark in the progression to cell death in response to dif-
ferent apoptotic stimuli [60,61].
Together, our results show that exposure of HepG2 cells to
growth-suppressive concentrations of apigenin resulted in ROS
generation, as indicated by increased DCF oxidation (Fig. 3),
accompanied by a signiﬁcant decrease in catalase mRNA expres-
sion levels and activity (Fig. 4A and B) and intracellular GSH deple-
tion (Fig. 5).
Three main mechanisms may contribute to Nrf2-mediated ARE
activation by ﬂavonoids [62], namely: (i) Nrf2 nuclear accumula-
tion as a consequence of its phosphorylation, through activation
of upstream kinases such as Akt and MAPKs; (ii) pro-oxidant action
of ﬂavonoids, resulting in oxidized cysteine thiols in Keap1; and
(iii) redox-cycling reactions leading to the formation of semiqui-
none radicals and O-quinine, which affects Keap1 activity. How-
ever, in human HepG2 cells, quercetin enhanced ARE activity by
upregulating Nrf2 expression, preventing its ubiquitination and
proteasomal degradation, and accelerating Keap1 degradation in
a proteasome-independent manner [63].
Recently it has been observed that luteolin (30,40,5,7-tetrahydr-
oxyﬂavone), is a potent Nrf2 inhibitor (reduces mRNA and protein
levels), and promoted GSH depletion of reduced glutathione in
non-small-cell lung cancer A549 cells [64].
In some lung cancer cell lines, GSH depletion has been found to
enhance Bax protein translocation to the mitochondrial mem-
brane, thus sensitizing cells to apoptosis [65]. Apoptotic cell death
of Mahlavu cells via an oxidative stress-mediated caspase-depen-
dent mechanism involves an initial overproduction of reactive oxy-
gen species (ROS), followed by a severe depletion of intracellular
GSH contents, which correlated with the severe drops in the mito-
chondrial transmembrane potential and the activation of caspases
3/7, resulting in the DNA fragmentation [66]. In addition, Ji et al.
[67] showed the effects of andrographolide (ANDRO), an active
compound isolated from a traditional medicinal herb, on the death
of apoptotic hepatoma cells. These authors observed that ANDRO
induced the activation of the ASK1–SEK1/MKK4–JNK-c-Jun signal
cascade, initiating the apoptosis, and suggested that there is a
crosstalk between JNK activation and cellular GSH homeostasis
[67]. They also observed that the depletion of cellular GSH can
potentiate the anti-cancer effects of ANDRO in hepatoma cells [67].
GSH depletion induced by apigenin in HepG2 cells may be
caused by increased ROS promoted by the pro-oxidant action of
apigenin. Increased ROS promotion by apigenin may be due to:
(i) oxidation of its hydroxyl groups; (ii) mitochondrial membrane
alterations; (iii) altered oxidases activity; and (iv) reduced catalase
mRNA expression and activity. Therefore, it seems reasonable to
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tions by direct interaction with the protein.
In addition, it is well established that cancer cells display a per-
sistently higher oxidative stress level compared to normal cells.
This effect may render cancer cells more susceptible to being killed
by anticancer drugs that promote increased ROS levels, such as
some phytochemicals [46]. Moreover, Nrf2 favors the potential of
cancer cells for chemoresistance in certain cancers [68,69].
Agents capable of inducing selective apoptosis of cancer cells
are receiving considerable attention in the effort to develop novel
cancer-preventive approaches. In the present study, we also dem-
onstrated that the human hepatoma HepG2 cell line is more sensi-
tive to apigenin-mediated cell death than are primary cultures of
mouse hepatocytes. Apigenin-treated HepG2 cells showed reduc-
tion in cell viability in a dose- and time-dependent manner, reach-
ing 45% and 65% reduction in the presence of 100 lmol/L apigenin
after 24 and 48 h of treatment, respectively (Fig. 1A). In contrast,
we observed a lower reduction in cell viability (20%) when pri-
mary-culture mouse hepatocytes were maintained under the same
experimental conditions (Fig. 7).
In agreement with our data, similar selective growth-inhibitory
effects were also observed for human A431 epidermoid carcinoma
cells, compared to normal human epidermal keratinocytes, and for
human prostate adenocarcinoma, compared to normal human
prostate epithelial cells [7]. The selective effect of apigenin in tu-
mor versus normal cells suggests that apigenin is a promising che-
mopreventive and/or chemotherapeutic agent against liver cancer.Conﬂict of interest
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